KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Long-Term Debt Repayments: 2021-2023

  • Halozyme Therapeutics' Long-Term Debt Repayments was N/A to $13.5 million in Q1 2023 from the same period last year, while for Mar 2023 it was $502.5 million, marking a year-over-year change of. This contributed to the annual value of $13.5 million for FY2023, which is 88.76% down from last year.
  • According to the latest figures from Q1 2023, Halozyme Therapeutics' Long-Term Debt Repayments is $13.5 million, which was up 110.37% from -$130.0 million recorded in Q4 2022.
  • In the past 5 years, Halozyme Therapeutics' Long-Term Debt Repayments registered a high of $369.1 million during Q4 2021, and its lowest value of -$130.0 million during Q4 2022.
  • Its 3-year average for Long-Term Debt Repayments is $125.6 million, with a median of $131.7 million in 2022.
  • Data for Halozyme Therapeutics' Long-Term Debt Repayments shows a maximum YoY plummeted of 135.22% (in 2022) over the last 5 years.
  • Quarterly analysis of 3 years shows Halozyme Therapeutics' Long-Term Debt Repayments stood at $369.1 million in 2021, then tumbled by 135.22% to -$130.0 million in 2022, then reached $13.5 million in 2023.
  • Its Long-Term Debt Repayments was $13.5 million in Q1 2023, compared to -$130.0 million in Q4 2022 and $250.0 million in Q3 2022.